Pharvaris (NASDAQ:PHVS) Forecasted to Earn FY2028 Earnings of $1.43 Per Share

Pharvaris (NASDAQ:PHVS) – Analysts at Wedbush issued their FY2028 earnings per share estimates for Pharvaris in a research note issued to investors on Thursday, April 11th. Wedbush analyst L. Chico forecasts that the company will post earnings per share of $1.43 for the year. Wedbush has a “Outperform” rating and a $35.00 price objective on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.15) per share.

Separately, JMP Securities increased their price target on Pharvaris from $49.00 to $50.00 and gave the company a “market outperform” rating in a research note on Thursday.

Pharvaris Trading Down 1.8 %

Pharvaris stock opened at $21.90 on Monday. The stock has a 50-day moving average of $25.01 and a two-hundred day moving average of $23.30. Pharvaris has a one year low of $7.93 and a one year high of $33.00.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Hudson Bay Capital Management LP acquired a new stake in shares of Pharvaris during the third quarter worth $812,000. Walleye Capital LLC boosted its holdings in shares of Pharvaris by 15.2% during the third quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock worth $1,691,000 after purchasing an additional 10,691 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Pharvaris during the fourth quarter worth $240,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Pharvaris during the fourth quarter worth $183,000. Finally, Bank of America Corp DE boosted its holdings in shares of Pharvaris by 1,054.4% during the first quarter. Bank of America Corp DE now owns 5,772 shares of the company’s stock worth $105,000 after purchasing an additional 5,272 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).